Literature DB >> 21138938

Capillary enlargement, not sprouting angiogenesis, determines beneficial therapeutic effects and side effects of angiogenic gene therapy.

Petra Korpisalo1, Jarkko P Hytönen, Johannes T T Laitinen, Svetlana Laidinen, Henna Parviainen, Henna Karvinen, Jaana Siponen, Varpu Marjomäki, Ismo Vajanto, Tuomas T Rissanen, Seppo Ylä-Herttuala.   

Abstract

AIMS: Currently, it is still unclear which mechanisms drive metabolic benefits after angiogenic gene therapy. The side-effect profile of efficient angiogenic gene therapy is also currently incompletely understood. In this study, the effects of increasing doses of adenoviral (Ad) vascular endothelial growth factor-A (VEGF-A) were evaluated on vascular growth, metabolic benefits, and systemic side effects. METHODS AND
RESULTS: Adenoviral vascular endothelial growth factor-A or AdLacZ control was injected intramuscularly (10(9)-10(11) vp/mL) or intra-arterially (5 × 10(11) vp/mL) into rabbit (n = 102) hindlimb muscles and examined 6 or 14 days later. Blood flow, tissue oedema, metabolic benefits, and the structure of angiogenic vessels were assessed using ultrasound imaging, modified Miles assay, arterial blood gas and metabolite analyses, and light and confocal microscopy, respectively. Safety analyses included cardiac ultrasound, electrocardiograms, and blood and tissue samples. Sprouting angiogenesis was already induced with low AdVEGF-A concentrations, whereas higher concentrations were needed to reach efficient capillary enlargement and increases in target muscle perfusion. Interestingly, metabolic benefits, such as improved aerobic energy metabolism and decreased metabolic acidosis during exercise, after AdVEGF-A administration were highly correlated to the level of capillary enlargement but not to sprouting angiogenesis. Several systemic dose-dependent side effects, including transient increases in liver, kidney, and pancreatic enzymes, and signs of cardiac effects were observed.
CONCLUSION: Efficient capillary enlargement leading to significant increases in tissue perfusion is needed to gain metabolic benefits after angiogenic gene therapy. However, the risk of systemic side effects can increase as the efficiency of angiogenic gene therapy is improved. Importantly, the unstable wall structure of the newly formed vessels seems not to compromise the metabolic benefits.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21138938     DOI: 10.1093/eurheartj/ehq433

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  10 in total

Review 1.  Restoring the renal microvasculature to treat chronic kidney disease.

Authors:  David A Long; Jill T Norman; Leon G Fine
Journal:  Nat Rev Nephrol       Date:  2012-02-07       Impact factor: 28.314

Review 2.  Cardiovascular Gene Therapy: Past, Present, and Future.

Authors:  Seppo Ylä-Herttuala; Andrew H Baker
Journal:  Mol Ther       Date:  2017-04-04       Impact factor: 11.454

3.  Long-lasting fibrin matrices ensure stable and functional angiogenesis by highly tunable, sustained delivery of recombinant VEGF164.

Authors:  Veronica Sacchi; Rainer Mittermayr; Joachim Hartinger; Mikaël M Martino; Kristen M Lorentz; Susanne Wolbank; Anna Hofmann; Remo A Largo; Jeffrey S Marschall; Elena Groppa; Roberto Gianni-Barrera; Martin Ehrbar; Jeffrey A Hubbell; Heinz Redl; Andrea Banfi
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-28       Impact factor: 11.205

4.  Induction of aberrant vascular growth, but not of normal angiogenesis, by cell-based expression of different doses of human and mouse VEGF is species-dependent.

Authors:  Edin Mujagic; Roberto Gianni-Barrera; Marianna Trani; Abdulsamie Patel; Lorenz Gürke; Michael Heberer; Thomas Wolff; Andrea Banfi
Journal:  Hum Gene Ther Methods       Date:  2013-02       Impact factor: 2.396

5.  Inducible VEGF expression by human embryonic stem cell-derived mesenchymal stromal cells reduces the minimal islet mass required to reverse diabetes.

Authors:  E Hajizadeh-Saffar; Y Tahamtani; N Aghdami; K Azadmanesh; M Habibi-Anbouhi; Y Heremans; N De Leu; H Heimberg; P Ravassard; M A Shokrgozar; H Baharvand
Journal:  Sci Rep       Date:  2015-03-30       Impact factor: 4.379

6.  Self-assembly of c-myc DNA promoted by a single enantiomer ruthenium complex as a potential nuclear targeting gene carrier.

Authors:  Qiong Wu; Wenjie Mei; Kangdi Zheng; Yang Ding
Journal:  Sci Rep       Date:  2016-07-06       Impact factor: 4.379

7.  Snake venom VEGF Vammin induces a highly efficient angiogenic response in skeletal muscle via VEGFR-2/NRP specific signaling.

Authors:  Pyry I Toivanen; Tiina Nieminen; Johanna P Laakkonen; Tommi Heikura; Minna U Kaikkonen; Seppo Ylä-Herttuala
Journal:  Sci Rep       Date:  2017-07-17       Impact factor: 4.379

8.  Intramyocardial Injection of Recombinant Adeno-Associated Viral Vector Coexpressing PR39/Adrenomedullin Enhances Angiogenesis and Reduces Apoptosis in a Rat Myocardial Infarction Model.

Authors:  Rui An; Cong Xi; Jian Xu; Ying Liu; Shumiao Zhang; Yuemin Wang; Yuewen Hao; Lijun Sun
Journal:  Oxid Med Cell Longev       Date:  2017-03-02       Impact factor: 6.543

9.  Mapping the transcriptomic changes of endothelial compartment in human hippocampus across aging and mild cognitive impairment.

Authors:  Daniel V Guebel; Néstor V Torres; Ángel Acebes
Journal:  Biol Open       Date:  2021-05-17       Impact factor: 2.422

10.  Improved endothelialization of small-diameter ePTFE vascular grafts through growth factor therapy.

Authors:  Jarkko P Hytönen; Olli Leppänen; Jouni Taavitsainen; Petra Korpisalo; Svetlana Laidinen; Kari Alitalo; Jonas Wadström; Tuomas T Rissanen; Seppo Ylä-Herttuala
Journal:  Vasc Biol       Date:  2019-01-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.